Becton, Dickinson and Company $BDX Holdings Cut by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Becton Dickinson stake by 99.7% in the third quarter, selling 424,808 shares and retaining 1,455 shares worth approximately $260,000. Institutional investors still own 86.97% of BDX.
• Analysts maintain a broadly neutral outlook, with a consensus “Hold” rating and an average price target of $185.07; ratings include seven Buys, nine Holds, and one Sell.
• BD exceeded quarterly expectations with adjusted EPS of $3.23 versus $3.14 expected and revenue of $4.98 billion, up 5.4% year over year. The company also pays a $1.05 quarterly dividend, equivalent to a 2.2% annualized yield.

Curated Wealth Partners LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 99.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,455 shares of the medical instruments supplier's stock after selling 424,808 shares during the quarter. Curated Wealth Partners LLC's holdings in Becton, Dickinson and Company were worth $260,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. SHP Wealth Management bought a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. grew its position in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD bought a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Bell Investment Advisors Inc purchased a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $29,000. Finally, Kelleher Financial Advisors purchased a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $30,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BDX shares. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday, August 7th. Barclays began coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an "underweight" rating and a $165.00 price target for the company. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. TD Cowen raised their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Finally, Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average price target of $185.07.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the firm's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company's stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

BDX opened at $191.34 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a market capitalization of $52.72 billion, a price-to-earnings ratio of 57.63, a PEG ratio of 12.93 and a beta of 0.21. The company has a fifty day moving average of $184.03 and a 200 day moving average of $163.70. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $195.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.